Gan & Lee Pharmaceuticals continues to invest in R&D in the field of chemical drugs and develops a pipeline of innovative chemical drugs focused on metabolic diseases and related therapeutic areas. Through a combination of independent R&D and collaborative development, the company continuously enriches its chemical drug product portfolio.
The following are Gan & Lee Pharmaceuticals' core chemical drug products.
Gandouvie®, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was launched in 2024 and passed the consistency evaluation, and is listed in Category B of the National Medical Insurance. It supports monotherapy/combination therapy for type 2 diabetes mellitus, administered once daily; it has good glycemic control and tolerability.
Ganshuangwei®, a fixed-dose combination of sitagliptin and metformin, was launched in 2026 and passed the evaluation, and was listed in Category B of the National Medical Insurance. It is for patients with inadequate control on metformin monotherapy, administered once daily. It has a lower incidence of hypoglycemia and gastrointestinal reactions compared to metformin monotherapy, and has good tolerability and treatment compliance.
Gantangxin®, a DPP-4 inhibitor, was launched in 2025 and passed the consistency evaluation, and was listed in Category B of the National Medical Insurance. It supports monotherapy/combination therapy for type 2 diabetes mellitus, administered once daily. No dose adjustment is required for patients with hepatic or renal insufficiency, and it is recommended by authoritative guidelines.
Ganxiujing®, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, was launched in 2025 and passed the consistency evaluation, and was listed in Category B of the National Medical Insurance. It is approved for indications of type 2 diabetes mellitus, heart failure, and chronic nephropathy, administered once daily; it has both glycemic control and cardio-renal protective effects.
